Schrodinger Inc
SDGR18.310USD
-0.070-0.38%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
More Details of Schrodinger Inc Company
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Schrodinger Inc Info
Ticker SymbolSDGR
Company nameSchrodinger Inc
IPO dateFeb 06, 2020
CEOFarid (Ramy Farid)
Number of employees891
Security typeOrdinary Share
Fiscal year-endFeb 06
Address1540 Broadway
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone15032991150
Websitehttps://www.schrodinger.com
Ticker SymbolSDGR
IPO dateFeb 06, 2020
CEOFarid (Ramy Farid)
Company Executives of Schrodinger Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.24M
+0.49%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
36.99K
-30.96%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
24.57K
-5.37%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
23.64K
+112.26%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
12.25K
+95.95%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
12.25K
+95.95%
Ms. Bridget Anne Van Kralingen
Ms. Bridget Anne Van Kralingen
Independent Director
Independent Director
11.50K
+14.99%
Mr. Michael Lynton
Mr. Michael Lynton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mannix Aklian
Mr. Mannix Aklian
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing
--
--
Mr. Gary Ginsberg, J.D.
Mr. Gary Ginsberg, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.24M
+0.49%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
36.99K
-30.96%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
24.57K
-5.37%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
23.64K
+112.26%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
12.25K
+95.95%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
12.25K
+95.95%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
On-premise software
15.74M
28.75%
Drug discovery services
13.94M
25.46%
Hosted software
11.13M
20.32%
Software maintenance
6.78M
12.38%
Contribution
4.51M
8.24%
Other
2.66M
4.85%
By RegionUSD
Name
Revenue
Proportion
United States
34.05M
62.18%
EMEA
13.56M
24.77%
APAC
6.97M
12.73%
Rest of World
175.00K
0.32%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
On-premise software
15.74M
28.75%
Drug discovery services
13.94M
25.46%
Hosted software
11.13M
20.32%
Software maintenance
6.78M
12.38%
Contribution
4.51M
8.24%
Other
2.66M
4.85%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.55%
Bill & Melinda Gates Foundation Trust
10.82%
The Vanguard Group, Inc.
9.81%
Rubric Capital Management LP
8.17%
Amova Asset Management Co., Ltd.
7.06%
Other
51.59%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.55%
Bill & Melinda Gates Foundation Trust
10.82%
The Vanguard Group, Inc.
9.81%
Rubric Capital Management LP
8.17%
Amova Asset Management Co., Ltd.
7.06%
Other
51.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.56%
Investment Advisor/Hedge Fund
29.79%
Hedge Fund
15.33%
Endowment Fund
10.82%
Research Firm
3.00%
Individual Investor
2.64%
Bank and Trust
1.57%
Pension Fund
0.90%
Venture Capital
0.17%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
545
71.77M
111.28%
-2.08M
2025Q2
572
66.46M
103.14%
-5.60M
2025Q1
593
67.21M
104.69%
-5.43M
2024Q4
576
64.44M
100.89%
-9.04M
2024Q3
581
67.44M
105.91%
-6.15M
2024Q2
573
64.76M
101.80%
-8.12M
2024Q1
574
63.48M
100.05%
-5.40M
2023Q4
584
62.06M
98.56%
-7.64M
2023Q3
586
63.62M
101.35%
-15.42M
2023Q2
584
64.04M
102.20%
-7.30M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.17M
12.68%
+419.13K
+5.41%
Jun 30, 2025
Bill & Melinda Gates Foundation Trust
6.98M
10.83%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
6.60M
10.25%
+74.93K
+1.15%
Jun 30, 2025
Rubric Capital Management LP
5.00M
7.76%
+200.00K
+4.17%
Jun 30, 2025
Amova Asset Management Co., Ltd.
3.65M
5.66%
+187.53K
+5.42%
Jun 30, 2025
Lazard Asset Management, L.L.C.
1.42M
2.2%
-198.96K
-12.30%
Jun 30, 2025
State Street Investment Management (US)
2.19M
3.39%
-26.19K
-1.18%
Jun 30, 2025
Stephens Investment Management Group, LLC
2.26M
3.51%
+291.39K
+14.79%
Jun 30, 2025
MFS Investment Management
1.49M
2.32%
-598.55K
-28.60%
Jun 30, 2025
ARK Investment Management LLC
1.96M
3.04%
-335.26K
-14.61%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
3.63%
Clough Select Equity ETF
3.12%
TrueShares Technology, AI & Deep Learning ETF
1.99%
Global X HealthTech ETF
1.14%
State Street SPDR FactSet Innovative Technolgy ETF
0.84%
Franklin Exponential Data ETF
0.82%
WisdomTree BioRevolution Fund
0.77%
Invesco S&P SmallCap Health Care ETF
0.72%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.47%
First Trust Multi-Manager Small Cap Opportunities ETF
0.47%
View more
ARK Genomic Revolution ETF
Proportion3.63%
Clough Select Equity ETF
Proportion3.12%
TrueShares Technology, AI & Deep Learning ETF
Proportion1.99%
Global X HealthTech ETF
Proportion1.14%
State Street SPDR FactSet Innovative Technolgy ETF
Proportion0.84%
Franklin Exponential Data ETF
Proportion0.82%
WisdomTree BioRevolution Fund
Proportion0.77%
Invesco S&P SmallCap Health Care ETF
Proportion0.72%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.47%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.47%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Schrodinger Inc?
The top five shareholders of Schrodinger Inc are:
BlackRock Institutional Trust Company, N.A. holds 8.17M shares, accounting for 12.68% of the total shares.
Bill & Melinda Gates Foundation Trust holds 6.98M shares, accounting for 10.83% of the total shares.
The Vanguard Group, Inc. holds 6.60M shares, accounting for 10.25% of the total shares.
Rubric Capital Management LP holds 5.00M shares, accounting for 7.76% of the total shares.
Amova Asset Management Co., Ltd. holds 3.65M shares, accounting for 5.66% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.17M shares, accounting for 12.68% of the total shares.
Bill & Melinda Gates Foundation Trust holds 6.98M shares, accounting for 10.83% of the total shares.
The Vanguard Group, Inc. holds 6.60M shares, accounting for 10.25% of the total shares.
Rubric Capital Management LP holds 5.00M shares, accounting for 7.76% of the total shares.
Amova Asset Management Co., Ltd. holds 3.65M shares, accounting for 5.66% of the total shares.
What are the top three shareholder types of Schrodinger Inc?
The top three shareholder types of Schrodinger Inc are:
BlackRock Institutional Trust Company, N.A.
Bill & Melinda Gates Foundation Trust
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Bill & Melinda Gates Foundation Trust
The Vanguard Group, Inc.
How many institutions hold shares of Schrodinger Inc (SDGR)?
As of 2025Q3, 545 institutions hold shares of Schrodinger Inc, with a combined market value of approximately 71.77M, accounting for 111.28% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 8.14%.
What is the biggest source of revenue for Schrodinger Inc?
In FY2025Q2, the On-premise software business generated the highest revenue for Schrodinger Inc, amounting to 15.74M and accounting for 28.75% of total revenue.
